Want more Traders News Source Research? Download our free mobile App. Search “Traders News Source” on the APP Store or Google Play.
BIOC has expanded its pathology partnership platform, EmpowerTCTM, to now offer local pathologists the ability to analyze prognostic and predictive markers on CTCs from a liquid biopsy using immunocytochemistry (ICC) methods. This new offering, in addition to an expanded biomarker menu, supplements the previous capabilities of Biocept’s proprietary pathology partnership platform to analyze liquid biopsy biomarkers using fluorescence in situ hybridization (FISH) methods.
_____________________________________________
Traders News Source recent picks, track record and about us – Free breakout reports in real time text the word Traders to 25827 – https://tradersnewssource.com/traders-news-source-new-members/
_____________________________________________
Recently, BIOC announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $8.2 million of its common stock in a registered direct offering and warrants to purchase shares of Common Stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $1.37. The gross proceeds to Biocept from the registered direct offering and concurrent private placement is expected to be approximately $8.2 million before deducting the placement agents’ fees and other estimated offering expenses. The registered direct offering and concurrent private placement is expected to close on or about March 19, 2019
The company’s abstract demonstrating the ability of the Company’s Target Selector™ liquid biopsy test to detect ESR1 mutations with high sensitivity has been accepted for a poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 at the Georgia World Congress Center in Atlanta.
Products
Target Selector™ ctDNA EGFR Kit
Best in class sensitivity—detect one copy of a mutant DNA among 10,000 wildtype
Proprietary and patented switch blocker technology—provides superior sensitivity and cost savings
More content per assay—amplify multiple mutations/variants in hot spot regions of interest in single reaction
Platform flexibility—used on variety of low-cost analytical platforms including qPCR and Sanger Sequencing
Proven assay technology—used in 20,000 tests to date
About
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company’s cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Analysts
Date Brokerage Action Rating
10/3/2018 Dawson James Reiterated Rating Buy
5/23/2018 Westpark Capital Downgrade Outperform ➝ Hold
Source: marketbeat.com
Financial review
Third Quarter Financial Results
Revenues for the third quarter of 2018 were $762,000. For the third quarter of 2018, revenues included $698,000 in commercial test revenues, and $63,000 in development services test revenues.
Cost of revenues for the third quarter of 2018 of $2.5 million was unchanged from the prior year period.
Research and development (R&D) expenses for the third quarter of 2018 were $1.1 million.
General and administrative (G&A) expenses for the third quarters of 2018 and 2017 were unchanged at $1.8 million.
Sales and marketing expenses for the third quarter of 2018 were $1.4 million.
The net loss for the third quarter of 2018 was $6.0 million, or $2.42 per share.
Stock influences and risk factors
If they cannot develop products, assays and services to keep pace with rapid advances in technology, medicine and science, their operating results and competitive position could be harmed.
If their sole laboratory facility becomes damaged or inoperable, their ability to sell and provide products and diagnostic assays and pursue research and development efforts may be jeopardized.
If they cannot compete successfully with competitors, they may be unable to increase or sustain revenues or achieve and sustain profitability.
If they are not able to retain and recruit personnel with the requisite technical skills, they may be unable to successfully execute the business strategy.
Stock chart
On Friday, March 15, 2019, BIOC shares closed at $1.17 per share on traded volume of 8 million shares. The current RSI (14) is 48.42
At $1.17 per share BIOC is trading below its 50 DMA and 200 DMA of $1.41 and $3.00 respectively.
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Mark Roberts. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
